Member Info for BasilAlderman

I totally agree with you. I have felt for a while that the share price is going to rise to circa 8-10p soon on the back of the Covid research update, which judging by the wording today is progressing very well and then a raise at around 8p will happen. What's not to like about that? I also reckon there could be cash from a big licencing deal soon, so a raise at a much higher price than our current SP might not even occur. We just need the Covid data to be published soon and the share price will soar.

Great shout Thoth re 500p + a share. Anything is possible.

The conclusion of Boil B's post www.nature.com/articles/s41375-021-01266-6 is yet another huge validation of Sareum and its science. You can't get better than "we found a potential role for JAK-inhibitors in reducing the risk of death in persons with COVID-19". As I said on Wednesday I really do feel that we could be about to experience a 2020 Synairgen moment, of 6p to 240p in the space of just a few months, with our own share price. FOMO will kick in shortly. Thanks Boil B for the post by the way. Keep them coming everyone.

This is patently a game changing moment for Sareum with the report disclosing that the results establish TYK2 as a potential therapeutic agent for the treatment of autoimmune diseases and severe COVID-19. It doesn’t get much better than that in our sector currently. It feels to me that we could be about to experience a 2020 Synairgen moment (6p to 240p in the space of just a few months) with our own share price, on the back of this incredible data. Surely now Stephen Parker, John Reader and Tim Mitchell, with the help of Dr Owen in particular, will be able to secure the mother of all deals imminently with a worldwide pharma company.

28p a share is looking realistic now and Thoth's "quid a share" prediction is certainly a possibility moving forward.

I would much prefer to see Sareum update the market via RNS or via a peer related update. What Stephen Parker is tweeting is of serious interest to the market / the wider investor community but he only has 374 followers on Twitter. It is a shame it was not via Sareum's own Twitter feed or as an RNS update, which would carry more weight. It is likely to just get missed by the masses this way. Come on Tim and John lets have a more formal briefing pre the interims to give the share price a shot in the arm. I'm hoping this info it's not just thrown away in the forthcoming interim results for the six months ended 30 December 2020, That would be a missed opportunity.

Funny that the wording is almost identical to what Brighty suggested at 7.51am today on here!! Proof that they clearly do read this thread and our daily musings. Well done all the LTH's for pushing the envelope yet again and being ahead of the curve. What an excellent board this is.

Workinginpharma, I tend to agree with your previous posts that we would be much better served as shareholders if the share price was 5-7p a share or above when news is released to give us the best chance of achieving a serious multibag. To achieve that we need some "news management". 28p will then be a reality.

Excellent point Brighty. Well worth a read. The suggested draft should be emailed to Stephen Parker and Tim Mitchell as this latest development regarding SRA737 and WEE1 is well worth a tweet and RNS. Sareum, their PR consultants and Nomad could do with a prompt. In the pharmaceutical sector 2020 proved that silence doesn't work - with the right kind of news we will be heading to Thoth's 28p party.

Thoth2 and Working, there is certainly something in this Dexamethasone SarTyk2 data to get excited about as Brighty1 was flagging it up here a few times yesterday and from memory has repeatedly linked it with our Tyk2 / Covid research. If that turns out to be correct then your 28p party will be happening very soon. Fingers crossed for the next few days.

I agree with you Gunner that a tweet, at the very least, would be helpful to spread the word that Sareum has data that demonstrates that its TYK2 works with Dexamethasone or better still include a line or two on this in the forthcoming company results RNS due any day now.

Maybe Michael Owen should replace Stephen Parker as the Chairman of Sareum then. Dr Owen clearly knows how to create value judging by his incredible success with Avacta and Kymab.

Aberystwyth, just an observation but when Sareum’s CSO is quoted in an RNS we have had more share price success of late:
US Patent Allowance: SDC-1802 TYK2/JAK1 Inhibitor - CSO
Thu, 8th Oct 2020 07:00
Share price increase from 0.91 to 1.53

Update on SRA737 Licensing Agreement - CEO
Thu, 12th Nov 2020 12:13
Share price decreases from 1.62p to 1.25p

Covid-19 Research Grant Confirmed - CSO
Thu, 3rd Dec 2020 07:00
Share price remains static at 1.43p

Nature article highlights role of TYK2 in Covid-19 - CSO
Mon, 14th Dec 2020 07:00
Share price increases 1.73p to 2.40p

US Patent Grant for TYK2/JAK1 Anticancer Candidate - CSO
Thu, 7th Jan 2021 07:00
Share price increases from 2.20p to 2.53p

Update re: FLT3+Aurora Kinase Inhibitor Programme - CEO
Fri, 8th Jan 2021 15:54
Share price decreases from 2.53p to 1.75p

A very encouraging & positive tweet today. Fingers crossed that we move to 2.5p - 3p ahead of the next news, which would give Sareum an excellent launchpad for our next move north towards.

Andy, well said. It is a non starter. It wouldn't get voted through and would see the BOD voted out, ValiRx style. No one wants to see that. Zero II's onboard. PI's hold the cards here in that scenario. That line of chat just detracts from the significant progress achieved by Sareum over recent months plus the excellent and pertinent conversation / investigative research every day here about the commercial monetisation and prospects of Sareum's science re Covid / 737 / SDC 1801/ 1802 / Chk1 Kinase TYK2/JAK1 Autoimmune / TYK2/JAK1 Cancer / Lupus / Aurora+FLT3 / Patents / Licencing / Pipeline / Takeover etc

Come on Guys, it is good that Sareum is presenting its wares at events like this. We need the wider investor community involved and aware of Sareum to enable the share price to continue to rise much higher in 2021. I think it is a positive move.

Spot on Ahfam, that's why we are here for 28p+. We can see from the RNS' and data what is going to happen with SAR. Once momentum and FOMO really kick in the MM's won't be able to restrain the SAR share price rise. I agree with the 80p per share post earlier today.

I agree with you and I wouldn’t disregard an SRA 737 RNS either. Since October the quantity of £10,000 buys at over 2p has been relentless. I have identified almost 100 or more of these in the last 3 months. Serious money is being invested in Sareum these days. No one wants to miss out on the next SNG, ODX, NCYT, AVCT style rise and Sareum is looking to be THE real deal. News could come anytime on many fronts.

The penny is starting to drop here for new and prospective investors that Sareum is the real deal and could replicate the huge share increases witnessed last year in this sector for Synairgen, Novacyt, Odx, Avacta etc.

The value of Sareum has just increased dramatically today on the back of that Kymab Sanofi deal. Interesting to note too that the acquisition is to be "paid in cash".